Epigenome engineering in cancer: Fairytale or a realistic path to the clinic?

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Falahi, Fahimeh ^a   Sgro, Agustin ^a   Blancafort, Pilar ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

CRISPR dCas9; DNA methylation; Epigenetics; Epigenome editing; Genome editing; Histone modifications; TALEs; Zinc finger proteins

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; ROMIDEPSIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR; UNTRANSLATED RNA; VORINOSTAT; ZINC FINGER PROTEIN;

CANCER GENE THERAPY; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DIABETIC NEUROPATHY; DNA METHYLATION; DNA REPAIR; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME INHIBITION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HORMONAL THERAPY; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84923628632     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00022     Document Type: Review

References (104)

1. Esteller M. Epigenetic changes in cancer. F1000 Biol Rep (2011) 3:9. doi: 10.3410/B3-9.
2. Simo-Riudalbas L, Esteller M. Cancer genomics identifies disrupted epigenetic genes. Hum Genet (2014) 133:713-25. doi:10.1007/s00439-013-1373-5.
3. Arnaudo AM, Garcia BA. Proteomic characterization of novel histone post-translational modifications. Epigenetics Chromatin (2013) 6:24. doi:10.1186/1756-8935-6-24.
4. Berger SL. The complex language of chromatin regulation during transcription. Nature (2007) 447:407-12. doi:10.1038/nature05915.
5. Turner BM. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol (2005) 12:110-2. doi:10.1038/nsmb0205-110.
6. Marmorstein R, Trievel RC. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta (2009) 1789:58-68. doi:10.1016/j.bbagrm.2008.07.009.
7. Henikoff S, Shilatifard A. Histone modification: cause or cog? Trends Genet (2011) 27:389-96. doi:10.1016/j.tig.2011.06.006.
8. Dong X, Greven MC, Kundaje A, Djebali S, Brown JB, Cheng C, et al. Modeling gene expression using chromatin features in various cellular contexts. Genome Biol (2012) 13:R53. doi:10.1186/gb-2012-13-9-r53.
9. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell (2007) 129:823-37. doi:10.1016/j.cell.2007.05.009.
10. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc (2006) 1:2353-64. doi:10.1038/nprot.2006.324.
11. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 13:484-92. doi:10.1038/nrg3230.
12. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol (2013) 14:341-56. doi:10.1038/nrm3589.
13. Rots MG, Petersen-Mahrt SK. The 2012 IMB Conference: DNA demethylation, repair and beyond. Institute of Molecular Biology, Mainz, Germany, 18-21 October 2012. Epigenomics (2013) 5:25-8. doi:10.2217/epi.12.73.
14. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem (2011) 286:35334-8. doi:10.1074/jbc.C111.284620.
15. Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG. Induced DNA demethylation by targeting ten-eleven translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res (2014) 42:1563-74. doi:10.1093/nar/gkt1019.
16. Quinodoz S, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol (2014) 24:651-63. doi:10.1016/j.tcb.2014.08.009.
17. Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription (2014) 5:e944014. doi:10.4161/21541272.2014.944014.
18. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 464:1071-6. doi:10.1038/nature08975.
19. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev (2010) 24:2264-9. doi:10.1101/gad.590910.
20. Watanabe T, Lin H. Posttranscriptional regulation of gene expression by Piwi proteins and piRNAs. Mol Cell (2014) 56:18-27. doi:10.1016/j.molcel.2014.09.012.
21. Reuter M, Berninger P, Chuma S, Shah H, Hosokawa M, Funaya C, et al. Miwi catalysis is required for piRNA amplification-independent LINE1 transposon silencing. Nature (2011) 480:264-7. doi:10.1038/nature10672.
22. Ross JP, Kassir Z. The varied roles of nuclear argonaute-small RNA complexes and avenues for therapy. Mol Ther Nucleic Acids (2014) 3:e203. doi:10.1038/mtna.2014.54.
23. Falahi F, van Kruchten M, Martinet N, Hospers GA, Rots MG. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res (2014) 16(4):412. doi:10.1186/s13058-014-0412-z.
24. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res (2009) 69:3802-9. doi:10.1158/0008-5472.CAN-08-3907.
25. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta (2011) 1815:75-89. doi:10.1016/j.bbcan.2010.10.002.
26. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res (2009) 15:3927-37. doi:10.1158/1078-0432.CCR-08-2784.
27. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2012) 22:246-58. doi:10.1101/gr.125872.111.
28. DeWoskin VA, Million RP. The epigenetics pipeline. Nat Rev Drug Discov (2013) 12:661-2. doi:10.1038/nrd4091.
29. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 28:1069-78. doi:10.1038/nbt.1678.
30. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 1:598-607. doi:10.1158/2159-8290.CD-11-0214.
31. Duijkers FA, de Menezes RX, Goossens-Beumer IJ, Stumpel DJ, Admiraal P, Pieters R, et al. Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cell Oncol (2013) 36:351-62. doi:10.1007/s13402-013-0140-x.
32. Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One (2010) 5:e12710. doi:10.1371/journal.pone.0012710.
33. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene (2005) 363:15-23. doi:10.1016/j.gene.2005.09.010.
34. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 10:935-54. doi:10.1586/era.10.62.
35. Misra S. Human gene therapy: a brief overview of the genetic revolution. J Assoc Physicians India (2013) 61:127-33.
36. Liu Q, Segal DJ, Ghiara JB, Barbas CF III. Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A (1997) 94:5525-30. doi:10.1073/pnas.94.11.5525.
37. Beltran AS, Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics (2011) 6(2):224-35. doi:10.4161/epi.6.2.13700.
38. Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene (2007) 26:2791-8. doi:10.1038/sj.onc.1210072.
39. Beltran AS, Blancafort P. Remodeling genomes with artificial transcription factors (ATFs). Methods Mol Biol (2010) 649:163-82. doi:10.1007/978-1-60761-753-2_10.
40. Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther (2008) 7:1080-90. doi:10.1158/1535-7163.MCT-07-0526.
41. Blancafort P, Jin J, Frye S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacol (2013) 83:563-76. doi:10.1124/mol.112.080697.
42. Beerli RR, Dreier B, Barbas CF III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A (2000) 97:1495-500. doi:10.1073/pnas.040552697.
43. Tan S, Guschin D, Davalos A, Lee YL, Snowden AW, Jouvenot Y, et al. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci U S A (2003) 100:11997-2002. doi:10.1073/pnas.2035056100.
44. Falahi F, Huisman C, Kazemier HG, van der Vlies P, Kok K, Hospers GA, et al. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol Cancer Res (2013) 11:1029-39. doi:10.1158/1541-7786.MCR-12-0567.
45. Mussolino C, Morbitzer R, Lutge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res (2011) 39:9283-93. doi:10.1093/nar/gkr597.
46. Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ. Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res (2014) 42:10856-68. doi:10.1093/nar/gku708.
47. Juarez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen GI, et al. Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors. Epigenetics (2013) 8:164-76. doi:10.4161/epi.23503.
48. Romer P, Recht S, Strauss T, Elsaesser J, Schornack S, Boch J, et al. Promoter elements of rice susceptibility genes are bound and activated by specific TAL effectors from the bacterial blight pathogen, Xanthomonas oryzae pv. oryzae. New Phytol (2010) 187:1048-57. doi:10.1111/j.1469-8137.2010.03217.x.
49. Pennisi E. The tale of the TALEs. Science (2012) 338:1408-11. doi:10.1126/science.338.6113.1408.
50. Gaj T, Gersbach CA, Barbas CF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 31:397-405. doi:10.1016/j.tibtech.2013.04.004.
51. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol (2013) 31:1137-42. doi:10.1038/nbt.2726.
52. Valton J, Dupuy A, Daboussi F, Thomas S, Marechal A, Macmaster R, et al. Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem (2012) 287:38427-32. doi:10.1074/jbc.C112.408864.
53. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol (1987) 169:5429-33.
54. Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol (2002) 43:1565-75. doi:10.1046/j.1365-2958.2002.02839.x.
55. Jansen R, van Embden JD, Gaastra W, Schouls LM. Identification of a novel family of sequence repeats among prokaryotes. OMICS (2002) 6:23-33. doi:10.1089/15362310252780816.
56. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 154:1380-9. doi:10.1016/j.cell.2013.08.021.
57. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 31:827-32. doi:10.1038/nbt.2647.
58. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol (2014) 32:677-83. doi:10.1038/nbt.2916.
59. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 32:279-84. doi:10.1038/nbt.2808.
60. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 32:569-76. doi:10.1038/nbt.2908.
61. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, et al. Targeted genome editing across species using ZFNs and TALENs. Science (2011) 333:307. doi:10.1126/science.1207773.
62. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 337:816-21. doi:10.1126/science.1225829.
63. de Groote ML, Kazemier HG, Huisman C, van der Gun BT, Faas MM, Rots MG. Upregulation of endogenous ICAM-1 reduces ovarian cancer cell growth in the absence of immune cells. Int J Cancer (2014) 134:280-90. doi:10.1002/ijc.28375.
64. Huisman C, Wisman GB, Kazemier HG, van Vugt MA, van der Zee AG, Schuuring E, et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by artificial transcription factors. Mol Oncol (2013) 7:669-79. doi:10.1016/j.molonc.2013.02.017.
65. Lund CV, Blancafort P, Popkov M, Barbas CF III. Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J Mol Biol (2004) 340:599-613. doi:10.1016/j.jmb.2004.04.057.
66. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res (2012) 40:6725-40. doi:10.1093/nar/gks360.
67. van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, Blancafort P, et al. Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer. Br J Cancer (2013) 108:881-6. doi:10.1038/bjc.2013.45.
68. Lara H, Wang Y, Beltran AS, Juarez-Moreno K, Yuan X, Kato S, et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 287:29873-86. doi:10.1074/jbc.M112.360768.
69. Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L, et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature (2013) 500:472-6. doi:10.1038/nature12466.
70. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 154:442-51. doi:10.1016/j.cell.2013.06.044.
71. Li Y, Moore R, Guinn M, Bleris L. Transcription activator-like effector hybrids for conditional control and rewiring of chromosomal transgene expression. Sci Rep (2012) 2:897. doi:10.1038/srep00897.
72. Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X, et al. Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res (2014) 42:4375-90. doi:10.1093/nar/gku109.
73. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods (2013) 10:973-6. doi:10.1038/nmeth.2600.
74. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2014) 32:267-73. doi:10.1038/nbt.2800.
75. Gao X, Tsang JC, Gaba F, Wu D, Lu L, Liu P. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res (2014) 42(20):e155. doi:10.1093/nar/gku836.
76. Xu GL, Bestor TH. Cytosine methylation targetted to pre-determined sequences. Nat Genet (1997) 17:376-8. doi:10.1038/ng1297-376.
77. Carvin CD, Parr RD, Kladde MP. Site-selective in vivo targeting of cytosine-5 DNA methylation by zinc-finger proteins. Nucleic Acids Res (2003) 31:6493-501. doi:10.1093/nar/gkg853.
78. van der Gun BT, Maluszynska-Hoffman M, Kiss A, Arendzen AJ, Ruiters MH, McLaughlin PM, et al. Targeted DNA methylation by a DNA methyltransferase coupled to a triple helix forming oligonucleotide to down-regulate the epithelial cell adhesion molecule. Bioconjug Chem (2010) 21:1239-45. doi:10.1021/bc1000388.
79. McNamara AR, Hurd PJ, Smith AE, Ford KG. Characterisation of site-biased DNA methyltransferases: specificity, affinity and subsite relationships. Nucleic Acids Res (2002) 30:3818-30. doi:10.1093/nar/gkf501.
80. Smith AE, Ford KG. Specific targeting of cytosine methylation to DNA sequences in vivo. Nucleic Acids Res (2007) 35:740-54. doi:10.1093/nar/gkl1053.
81. Nomura W, Barbas CF III. In vivo site-specific DNA methylation with a designed sequence-enabled DNA methylase. J Am Chem Soc (2007) 129:8676-7. doi:10.1021/ja0705588.
82. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, Ragozin S, et al. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res (2007) 35:100-12. doi:10.1093/nar/gkl1035.
83. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics (2012) 7:350-60. doi:10.4161/epi.19507.
84. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS One (2014) 9:e87703. doi:10.1371/journal.pone.0087703.
85. Snowden AW, Gregory PD, Case CC, Pabo CO. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol (2002) 12:2159-66. doi:10.1016/S0960-9822(02)01391-X.
86. Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK, et al. Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol (2013) 31:1133-6. doi:10.1038/nbt.2701.
87. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell (2013) 155:1479-91. doi:10.1016/j.cell.2013.12.001.
88. Carlson DF, Fahrenkrug SC, Hackett PB. Targeting DNA with fingers and TALENs. Mol Ther Nucleic Acids (2012) 1:e3. doi:10.1038/mtna.2011.5.
89. Davis D, Stokoe D. Zinc finger nucleases as tools to understand and treat human diseases. BMC Med (2010) 8:42. doi:10.1186/1741-7015-8-42.
90. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol (2013) 14:49-55. doi:10.1038/nrm3486.
91. High K, Gregory PD, Gersbach C. CRISPR technology for gene therapy. Nat Med (2014) 20:476-7. doi:10.1038/nm.3566.
92. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 32:551-3. doi:10.1038/nbt.2884.
93. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell (2014) 156:836-43. doi:10.1016/j.cell.2014.01.027.
94. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 514:380-4. doi:10.1038/nature13589.
95. Wang J, Quake SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 111:13157-62. doi:10.1073/pnas.1410785111.
96. Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol (2014) 88:11965-72. doi:10.1128/JVI.01879-14.
97. Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, et al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int (2014) 2014:612823. doi:10.1155/2014/612823.
98. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 3:2510. doi:10.1038/srep02510.
99. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 111:11461-6. doi:10.1073/pnas.1405186111.
100. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids (2014) 3:e186. doi:10.1038/mtna.2014.38.
101. Nakamura K, Fujii W, Tsuboi M, Tanihata J, Teramoto N, Takeuchi S, et al. Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep (2014) 4:5635. doi:10.1038/srep05635.
102. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science (2014) 345:1184-8. doi:10.1126/science.1254445.
103. Fiszman GL, Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer (2011) 2011:352182. doi:10.4061/2011/352182.
104. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol (2013) 425:479-91. doi:10.1016/j.jmb.2012.11.038.